natgillin/translations-raw huggingface dataset:
Therefore, the use of telmisartan is not recommended. 
Stoga se ne preporučuje primjena telmisartana.
Symptoms 
Simptomi:
Urinary tract infection including cystitis, upper respiratory tract infection including pharyngitis and sinusitis 
Infekcije mokraćnog sustava uključujući cistitis, infekcije gornjeg dišnog sustava uključujući faringitis i sinusitis
Telmisartan Teva is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Telmisartan Teva je kontraindiciran u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
Telmisartan showed a similar effect to ramipril in reducing the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure. 
Telmisartan je pokazao sličan učinak ramiprilu u smanjenju primarnog složenog ishoda kojeg čine kardiovaskularna smrt, nefatalni infarkta miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca.
• Biliary obstructive disorders 
- Bilijarni opstruktivni poremećaji.
Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion, and in a risk of hypotension when initiating therapy with telmisartan. 
Prethodno liječenje visokim dozama diuretika, kao što su furosemid (diuretik Henleove petlje) i hidroklorotiazid (tiazidni diuretik) može rezultirati deplecijom volumena kao i povećanim rizikom od hipotenzije pri započinjanju terapije telmisartanom.
If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan Teva. 
Ako se nešto od prethodno navedenog odnosi na Vas, obavijestite liječnika ili ljekarnika prije početka uzimanja Telmisartan Teva.
Chest pain, asthenia (weakness) 
Bol u prsima, astenija (slabost)
Potassium sparing diuretics or potassium supplements 
Diuretici koji štede kalij ili dodaci kalija
Tell your doctor if you are breast-feeding or about to start breast-feeding. 
Obavijestite liječnika ako dojite ili trebate početi dojiti.
Patients were randomized to one of the three following treatment groups: telmisartan 80 mg (n = 8542), ramipril 10 mg (n = 8576), or the combination of telmisartan 80 mg plus ramipril 10 mg (n = 8502), and followed for a mean observation time of 4.5 years. 
ramipril 10 mg (n = 8576) ili kombinacija telmisartana 80 mg i ramiprila 10 mg (n = 8502) uz prosječno trajanje praćenja od 4,5 godina.
The incidence of the primary endpoint was similar in the telmisartan (16.7 %) and ramipril (16.5 %) groups. 
(16,7 %) i ramiprilu (16,5 %).
The elimination half-life is not changed in patients with hepatic impairment. 
Poluvrijeme eliminacije nije promijenjeno u bolesnika s oštećenjem jetrene funkcije.
In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. 
U pojedinih bolesnika s narušenom funkcijom bubrega (npr. dehidrirani bolesnici ili stariji bolesnici s narušenom funkcijom bubrega), istodobna primjena antagonista receptora angiotenzina II i inhibitora ciklooksigenaze može rezultirati daljnjim pogoršanjem bubrežne funkcije, uključujući moguće akutno zatajenje bubrega koje je obično reverzibilno.
Muscoloskeletal and connective tissue disorders 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva
Pharmachemie B.V. Swensweg 5, 2031 GA, Haarlem, The Netherlands 
Swensweg 5, 2031 GA, Haarlem, Nizozemska
In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC0-24 and Cmax of ramipril and ramiprilat. 
U jednom ispitivanju istodobna primjena telmisartana i ramiprila dovela je do porasta do 2,5 puta u
The concomitant use of Telmisartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1). 
Istodobna primjena Telmisartana Teva s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove
Blood and the lymphatic system disorders Uncommon 
Poremećaji krvi i limfnog sustava Manje često:
- Intercurrent events, in particular dehydratation, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extend trauma). 
- Interkurentni događaji, osobito dehidracija, akutna kardijalna dekompenzacija, metabolička acidoza, pogoršanje funkcije bubrega, iznenadno pogoršanje stanja bubrega (npr. infektivne bolesti), liza stanica (npr. akutna ishemija uda, rabdomioliza, produljena trauma).
If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended. 
Ako je primjena kombinacije dokazano potrebna, preporučuje se pažljivo pratiti razine litija u serumu.
When initiating telmisartan therapy for the reduction of cardiovascular morbidity, close monitoring of blood pressure is recommended, and if appropriate adjustment of medications that lower blood pressure may be necessary. 
Kada se započinje terapija telmisartanom zbog smanjenja kardiovaskularnog morbiditeta, potrebne su redovne kontrole krvnog tlaka te, ako je potrebno, prilagodba doze drugih antihipertenziva.
Telmisartan Teva 40 mg Tablets Telmisartan 
Telmisartan Teva 40 mg tablete telmisartan
The blood pressure lowering effect of telmisartan can be increased by concomitant use of other antihypertensive medicinal products. 
Antihipertenzivni učinak telmisartana se može povećati istodobnom primjenom drugih antihipertenziva.
Hepatic function abnormal / liver disorder 
Abnormalna funkcija jetre/poremećaj rada jetre
In the PRoFESS trial, an increased incidence of sepsis was observed with telmisartan compared with placebo. 
U ispitivanju PRoFESS, uočena je povećana incidencija sepse s telmisartanom u usporedbi s placebom.
These pharmacologically-mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation. 
Ove farmakološki posredovane nuspojave, poznate iz pretkliničkih ispitivanja s inhibitorima angiotenzin konvertirajućeg enzima i antagonistima receptora angiotenzina II, bile su spriječene oralnim nadomjeskom soli.
Children and adolescents The use of Telmisartan Teva in children and adolescents up to the age of 18 years is not recommended. 
Djeca i adolescenti Primjena Telmisartana Teva u djece i adolescenata do dobi od 18 godina se ne preporučuje.
Limited experience is available in patients with severe renal impairment or haemodialysis. 
Postoji ograničeno iskustvo u bolesnika s teškim oštećenjem funkcije bubrega ili na hemodijalizi.
For treatment of high blood pressure, the usual dose of Telmisartan Teva for most patients is 40 mg once a day to control your blood pressure over the 24-hour period. 
Za terapiju povišenog krvnog tlaka uobičajena doza Telmisartana Teva za većinu bolesnika je jedna tableta od 40 mg jedanput na dan za kontrolu krvnog tlaka tijekom 24 sata.
Please note that instructions on how to remove the tablet from the blister strip are given on the outer carton of the peelable blisters. 
Upute kako izvaditi tabletu iz blistera su naznačene na kutiji blistera s odvojivim slojem.
Interstinal lung disease4 
Bolest plućnog intersticija4
Eosinophilia, thrombocytopenia 
Eozinofilija, trombocitopenija
Non-steroidal anti-inflammatory medicinal products 
Nesteroidni protuupalni lijekovi
Very rare side effects (may affect up to 1 in 10,000 people): 
Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba):
At the beginning of the preventive therapy with Micardis 80 mg, blood pressure should be frequently monitored. 
Na početku preventivnog liječenja s Telmisartana Teva od 80 mg, krvni tlak treba redovito pratiti.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). 
Dvostruka blokada renin-angiotenzin-aldosteronskog sustava (RAAS) Postoje dokazi da istodobna primjena ACE inhibitora, blokatora angiotenzin II receptora ili aliskirena povećava rizik od hipotenzije, hiperkalemije i smanjene bubrežne funkcije (uključujući akutno zatajenje bubrega).
Angiotensin II is a substance occurring in the body, which causes your blood vessels to narrow, thus increasing your blood pressure. 
Angiotenzin II je tvar koja nastaje u tijelu i dovodi do sužavanja krvnih žila, čime se povisuje krvni tlak.
(TPW) Tel.: +36 1 288 64 00 
Teva Gyógyszergyár Zrt. (TPW) Tel.: +36 1 288 64 00
Pharmachemie B.V. Swensweg 5, 2031 GA Haarlem, The Netherlands 
Swensweg 5, 2031 GA Haarlem, Nizozemska
Angiotensin II receptor antagonists should not be initiated during pregnancy. 
Trudnoća Primjena antagonista receptora angiotenzina II ne smije započeti tijekom trudnoće.
Other conditions with stimulation of the renin-angiotensin-aldosterone system In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8). 
U bolesnika čiji vaskularni tonus i funkcija bubrega ovise prvenstveno o djelovanju sustava reninangiotenzin-aldosteron (npr. bolesnici s teškim kongestivnim zatajenjem srca ili osnovnom bolešću bubrega, uključujući stenozu bubrežne arterije), liječenje lijekovima koji utječu na ovaj sustav, kao što je telmisartan, je povezano s akutnom hipotenzijom, hiperazotemijom, oligurijom ili rijetko, akutnim zatajenjem bubrega (vidjeti dio 4.8).
Renal impairment and kidney transplantation 
Oštećenje funkcije bubrega i transplantacija bubrega
Telmisartan Teva blocks this effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. 
Telmisartan Teva blokira učinak angiotenzina II, tako da se krvne žile šire, a krvni tlak snižava.
There was evidence for a benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p = 0.048)]. 
Dokazana je korist liječenja telmisartanom u usporedbi s placebom u prethodno određenom sekundarnom složenom ishodu od kardiovaskularne smrti, nefatalnog infarkta miokarda i nefatalnog moždanog udara [0,87 (95 % CI 0,76 - 1,00, p = 0,048)].
Telmisartan Teva is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Telmisartan Teva se ne preporučuje u ranoj trudnoći te se ne smije uzimati ako ste trudni dulje od 3 mjeseca, jer može izazvati teška oštećenja kod Vašeg djeteta ako se primjenjuje nakon trećeg mjeseca trudnoće.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of blisters 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kutija za blistere
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy. 
ACE inhibitori i blokatori angiotenzin II receptora ne smiju se primjenjivati istodobno u bolesnika s dijabetičkom nefropatijom.
If your liver is not working properly, the usual dose should not exceed 40 mg once a day. 
U bolesnika s oštećenom jetrom, uobičajena doza ne smije prelaziti 40 mg jedanput na dan.
Urinary tract infections, upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood. 
Infekcije mokraćnih puteva, infekcije gornjih dišnih puteva (npr. grlobolja, upala sinusa, česta prehlada), nedostatak crvenih krvnih stanica (anemija), visoke razine kalija, otežano uspavljivanje, osjećaj tuge (depresija), nesvjestica (sinkopa), osjećaj vrtnje (vrtoglavica), usporen rad srca (bradikardija), nizak krvni tlak (hipotenzija) u korisnika liječenih zbog visokog krvnog tlaka, omaglica pri ustajanju (ortostatska hipotenzija), nedostatak zraka, kašalj, bol u trbuhu, proljev, nelagoda u trbuhu, nadutost, povraćanje, svrbež, pojačano znojenje, osip na lijek, bol u leđima, grčevi mišića, bol mišića (mialgija), poremećaj rada bubrega uključujući akutno zatajenje bubrega, bol u prsima, osjećaj slabosti i povišena razina kreatinina u krvi.
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). 
Poznato je da izloženost antagonistima receptora angiotenzina II tijekom drugog i trećeg tromjesečja inducira fetotoksičnost u ljudi (smanjenje funkcije bubrega, oligohidramnij, usporena osifikacija kostiju lubanje) i neonatalnu toksičnost (zatajenje bubrega, hipotenzija, hiperkalijemija) (vidjeti dio
Progressive scarring of lung tissue (interstitial lung disease). 
Progresivno (napredujuće) stvaranje ožiljka u tkivu pluća (intersticijalna bolest pluća)**.
Telmisartan Teva is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Telmisartan Teva se ne preporučuje u ranoj trudnoći i ne smije se uzimati ako ste trudni dulje od 3 mjeseca jer može izazvati teška oštećenja Vašeg djeteta ako se primjenjuje u ovom stadiju (vidjeti dio o trudnoći).
ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on cardiovascular outcomes in 25620 patients aged 55 years or older with a history of coronary artery disease, stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population at risk for cardiovascular events. 
Endpoint Trial) uspoređivalo je učinke telmisartana, ramiprila i kombinacije telmisartana i ramiprila na kardiovaskularne ishode u 25 620 bolesnika u dobi od 55 godina ili starijih, s anamnezom koronarne arterijske bolesti, moždanog udara, TIA-e, periferne arterijske bolesti ili s dijabetes melitusom tipa 2 s dokazanim oštećenjima ciljnih organa (npr. retinopatija, hipertrofija lijeve klijetke, makro- ili mikroalbuminurija), koji su populacija s rizikom pojave kardiovaskularnih događaja.
In the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events, hyperkalaemia may be fatal. 
U starijih osoba, bolesnika s insuficijencijom bubrega, dijabetičara, bolesnika koji se istodobno liječe drugim lijekovima koji mogu povećati razinu kalija i/ili bolesnika s interkurentnim događajima,
If concomitant use is indicated because of documented hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. 
Ako je indicirana istodobna primjena zbog zabilježene hipokalijemije, primjenjuje ih se oprezno i uz učestalo praćenje kalija u serumu.
• manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or 
- manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca,
Telmisartan is not removed by haemodialysis. 
Telmisartan se ne uklanja hemodijalizom.
Cases of interstitial lung disease have been reported from post-marketing experience in temporal association with the intake of telmisartan. 
Nakon stavljanja lijeka u promet zabilježena je vremenska povezanost slučajeva intesticijske bolesti pluća s unosom telmisartana.
Your doctor has recommended a higher dose of one 80 mg tablet daily. 
Liječnik Vam može preporučiti višu dozu odnosno jednu tabletu od 80 mg jedanput na dan.
Telmisartan Teva is provided in peelable perforated unit-dose aluminium-aluminium blisters and perforated unit-dose aluminium-aluminium blisters containing 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for each type of blister presentation, although not all pack sizes may be marketed. 
Telmisartan Teva je dostupan u aluminij-aluminij perforiranim blisterima s odvojivim slojem djeljivima na jedinične doze i aluminij-aluminij perforiranim blisterima djeljivima na jedinične doze, svaka vrsta blistera sadrži 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tableta, iako se na tržištu se ne moraju nalaziti sve veličine pakovanja.
The other side of the tablet is debossed with the number "7460". 
Na drugoj strani tablete s utisnut je broj "7460".
Tel: +(39) 028917981 
Teva Italia S.r.l. Tel: +(39) 028917981
When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). 
Kada se utvrdi trudnoća, liječenje antagonistima receptora angiotenzina II mora se trenutno prekinuti te, ako je potrebno, započeti s primjenom drugog lijeka (vidjeti dijelove 4.3 i
No posology adjustment is required for patients with mild to moderate renal impairment. 
Nije potrebno prilagođavati doziranje u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega.
If you suffer from a condition called “orthostatic hypotension” (a drop in blood pressure on standing up from a sitting or lying position resulting in dizziness or faintness) your condition may worsen if you take Telmisartan Teva in combination with: 
Ako patite od stanja koje se naziva “ortostatska hipotenzija” (pad krvnog tlaka, tijekom ustajanja iz sjedećeg ili ležećeg položaja, koji dovodi do omaglice ili nesvjestice)
Interstitial lung disease 
Bolest plućnog intersticija
Rare side effects (may affect up to 1 in 1,000 people): 
Rijetke nuspojave (mogu se javiti u manje od 1 na 1000 osoba):
Metabolism and nutrition disorders Uncommon 
Poremećaji metabolizma i prehrane
Back pain (e.g. sciatica), muscle spasms, myalgia 
Bol u leđima (npr. išijas), grčevi mišića, mijalgija,
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 30 tablets 
14x1 tableta 28x1 tableta 30x1 tableta 40x1 tableta 56x1 tableta 60x1 tableta 84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta 30 tableta
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13). 
CI 0,93 - 1,10, p (neinferiornost) = 0,0019 na granici od 1,13).
The other side of the tablet is debossed with the number "7459". 
Na drugoj strani tablete je utisnut broj "7459".
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 
14x1 tableta 28x1 tableta 30x1 tableta 40x1 tableta 56x1 tableta 60x1 tableta 84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of peelable blisters 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kutija za blistere s odvojivim slojem
These patients can be expected to have reduced hepatic clearance for telmisartan. 
U ovih bolesnika očekuje se smanjeni klirens telmisartana u jetri.
The other side of the tablet is debossed with the number "7458". 
Na drugoj strani tablete utisnut je broj "7458".
- Elevated potassium levels in your blood - Diabetes 
- Povišene razine kalija u krvi.
Corticosteroïds (systemic route) Reduction of the antihypertensive effect. 
Kortikosteroidi (sistemski put primjene)
Nervous system disorders Uncommon: 
Poremećaji živčanog sustava Manje često:
The safety and efficacy of Telmisartan Teva in children and adolescents aged below 18 years have not been established. 
Sigurnost i djelotvornost Telmisartan Teve kod djece i adolescenata u dobi ispod 18 godina još uvijek nisu utvrđene.
In the “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)]. 
U ispitivanju „Preventivni režim za učinkovito izbjegavanje drugog moždanog udara“ (PRoFESS, od engl.“Prevention Regimen For Effectively avoiding Second Strokes”) u bolesnika u dobi od 50 godina i starijih, koji su nedavno imali moždani udar, zabilježena je povećana incidencija sepse za telmisartan u usporedbi s placebom, 0,70 % u odnosu na 0,49 % [RR 1,43 (95 % interval pouzdanosti 1,00
- The active substance is telmisartan. 
Što Telmisartan Teva sadrži - Djelatna tvar je telmisartan.
Alternatively, Telmisartan Teva may be used in combination with diuretics (“water” tablets) such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Telmisartan Teva. 
Alternativno, Telmisartan Teva se može primjenjivati u kombinaciji s diureticima (tablete za mokrenje), kao što je hidroklorotiazid za koji se pokazalo da ima dodatan učinak snižavanja krvnog tlaka s Telmisartanom Teva.
Other 
DRUGO
Adverse reactions have been ranked under headings of frequency using the following convention: 
Opći poremećaji i reakcije na mjestu primjene Manje često:
Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which has been shown to have an additive blood pressure lowering effect with telmisartan. 
Kao alternativa, telmisartan se može primjenjivati u kombinaciji s tiazidnim diureticima, kao što je hidroklorotiazid, za koji se pokazalo da ima dodatan učinak na snižavanje krvnog tlaka s telmisartanom.
METHOD AND ROUTE(S) OF ADMINISTRATION Oral use 
5. NAČIN I PUT(EVI) PRIMJENE LIJEKA